An Initiative of AVAC

Zambia

A snapshot of PrEP scale-up, registration and resources for Zambia.

  • 233,000-234,000
    Estimated Cumulative Number of People Initiating PrEP

    Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

  • 89,000
    PEPFAR PrEP Target in COP 2022

    Targets are set by PEPFAR country teams on an annual basis. Targets do not indicate funding is available for PrEP.

Data Updated: April 11, 2022

Drug Registration Status

  • Gilead's Truvada (TDF/FTC) registration
    Approved
  • Generic versions of TDF/FTC for prevention
    Approved
  • Viiv’s Apretude (CAB for PrEP) Registration
    Not approved
  • IPM’s Dapivirine Ring Registration
    Under review

Types of Delivery Projects

  • Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program.

Policy Framework

Funding

  • The Bill & Melinda Gates Foundation
  • Nike Foundation
  • PEPFAR

Eligibility Criteria

Oral PrEP is the use of antiretroviral (ARV) drugs before HIV exposure by people who are not infected with HIV to block the acquisition of HIV. Twelve trials on the effectiveness of oral PrEP have been conducted among serodiscordant couples, heterosexual men, women, men who have sex with men, people who inject drugs and transgender women. Where adherence has been high, significant levels of efficacy have been achieved, showing the value of this intervention as part of combination prevention approaches. WHO recommends oral PrEP containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches.

Recommendations:

  • Oral PrEP should be initiated to negative partner in a serodiscordant relationship whose HIV positive partner has refused to initiate cART.
  • Persons engaged in high-risk activities may also be considered for PrEP.
  • HIV testing is required before PrEP is offered.
  • Repeat HIV testing is recommended while PrEP is taken every three months.
  • The frequent HIV testing during PrEP use should also ideally become an opportunity for STI screening and management.
  • Those diagnosed HIV positive should be maintained on the same regimen.
  • PrEP should be provided as part of the combination prevention package (with condom use, HTS, family planning, STI testing etc).

Resources for Zambia